Transapical Aortic Blood Pump Layout for Higher Flow Output
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Transluminally-delivered LV blood pumps are constrained by size, limiting their ability to provide the desired amount of blood flow output.
Innovation Solution
A transapically-delivered LV blood pump is positioned in the ascending aorta, allowing a larger cross-sectional design capable of pumping at least 3 liters of blood per minute, with power and data transmission via a lead through the subclavian artery to a controller or power source, using wireless methods like Transcutaneous Energy Transfer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If transluminally-delivered LV blood pumps are used, then the implantation procedure is less invasive, but the pump size is constrained and cannot provide the desired amount of blood flow output
Solution Approach 1:
The implantation procedure is divided into two separate accesses: a transapical access for delivering the pump body to achieve high blood flow output, and a transclavicular access for delivering the lead separately. This segmentation allows each component to be optimized independently - the pump can be larger for better performance while the lead can be routed through a less invasive path.
Solution Approach 2:
The patent uses the ascending aorta as an intermediary pathway to transport the pump from the left ventricle to the aortic valve region. This intermediary space allows the pump to be delivered through the transapical approach without requiring direct manipulation in confined spaces, enabling larger pump designs while maintaining relatively minimally invasive access.
2Productivity
If a larger pump is used to provide desired blood flow output, then the blood flow capability is improved, but the implantation procedure becomes more invasive
Solution Approach 1:
The system separates the pump delivery path (transapical for large pump placement) from the lead delivery path (transclavicular for minimal invasion). This allows the pump to be sized for optimal blood flow performance while the lead insertion remains minimally invasive, resolving the contradiction between pump size and implantation invasiveness.
3Ease of operation
If the lead is pulled through the subclavian artery, then power and data transmission is achieved with minimal invasion, but the lead positioning and pump delivery coordination becomes complex
Solution Approach 1:
The lead is delivered and positioned through the subclavian artery before the pump is fully deployed. This preliminary action allows the electrical connection pathway to be established first, simplifying the coordination of the complex dual-access procedure and ensuring power transmission capability is ready before pump activation.
Solution Approach 2:
The patent uses the ascending aorta and aortic valve region as an intermediary space where the pump is temporarily positioned during delivery. This intermediary positioning allows independent delivery of the lead through the subclavian artery and the pump through the transapical approach, reducing the coordination complexity by allowing separate delivery paths to converge at a common destination zone.
Data Source
Figure 1a~1b
Figure 1c
Figure 1c~1e
AI summary
A disclosed apparatus or method can include or use a non-transluminally implantantable blood pump housing, which can be sized and shaped to be implanted at an aortic valve of a human subject, the pump housing can include: a pump housing cross-sectional profile size that is larger than is passable via a blood vessel of the human subject; and a power connection, configured for being electrically connected to an intravascular lead that is sized and shaped to extend from the pump housing through a subclavian artery of the human subject.